Page 1

OmniAb Highlights Partner Pipeline , xPloration® Plans and Outlook , and Introduces the OmniTides TM Platform at Investor & Analyst Day 10/06/2026 Formal presentation begins today , October 6 , 2026 , at 11 a.m. ET EMERYVILLE , Calif .-- ( BUSINESS WIRE ) -- OmniAb , Inc. ( NASDAQ : OABI ) , a provider of cutting - edge discovery research technology to enable the discovery of next - generation therapeutics , today hosts its Investor & Analyst Day in Emeryville , CA. With a full presentation agenda , the event highlights recent partner developments , the broader roll out of the xploration® platform , and introduces the OmniTides T peptide discovery platform and brand . TM " We look forward to bringing together our investment community and sharing a closer look at our technologies and capabilities , our strategy and the exciting opportunities ahead , ” said Matt Foehr , Chief Executive Officer of OmniAb . “ At our Investor & Analyst Day , we have the opportunity to discuss our priorities and our plans related to our increasingly efficient business model , review the variety of ways we are creating value with technology licensing , and outline how we are positioning the company for sustainable , long - term growth . Those attending here at our Emeryville headquarters are also getting to experience demonstrations of our powerful xPloration platform , that we see as an additional pillar of significant value and growth for the business . " Featured Highlights at the Investor & Analyst Day : OmniAb is highlighting its partner pipeline and partnerships as a key pillar of value for the business , with substantial contracted downstream potential milestones and royalties from a growing portfolio of later- stage programs that are described as best - in - class or first - in - class by its partners . Based on partner disclosures , OmniAb sees potential for primary completion of as many as 19 clinical trials evaluating OmniAb - derived drugs in the remaining months of 2026 and in 2027. OmniAb's broad and growing base of partnerships provides a unique vantage point on the industry and informs the company's strategic priorities as it leverages its highly differentiated suite of technologies . xploration Platform – Plans and Outlook Beginning this month , the xPloration platform will be available for purchase by all customers , expanding commercial access beyond the Partner Access Program launched in 2025. Informed by positive partner feedback and primary market research , the broader launch of xPloration addresses a market opportunity of more than $ 500 million . xploration is an Al - powered , high - throughput single B - cell screening platform designed to streamline antibody discovery workflows by screening millions of antibody - secreting B cells and rapidly recovering thousands of antibody sequences , that :